GRAIL (GRAL) is in focus after multiple law firms filed securities fraud class action lawsuits, following disclosure that its NHS Galleri cancer trial did not meet its primary endpoint and was linked to sharp investor losses.
See our latest analysis for GRAIL.
After the initial 50% drop following the NHS Galleri trial disclosure, GRAIL's recent momentum has picked up, with a 30 day share price return of 22.17% and a 90 day share price return of 46.86%. The 1 year total shareholder return stands at 89.77%.
If this kind of sharp move has you looking for other healthcare ideas, it could be a good moment to scan 40 healthcare AI stocks.
Bulls see GRAIL’s rebound and cancer testing portfolio as support for a rerate, while bears point to trial disappointment, ongoing losses and fresh litigation. How does the current valuation stack up against those competing stories?
Most Popular Narrative: 10.8% Overvalued
At a last close of $73.12 versus a fair value estimate of $66, the most followed GRAIL narrative frames the stock as pricing in a premium and anchors that view on clinical and reimbursement milestones.
Ongoing positive clinical trial results, including substantially higher cancer detection and positive predictive value with consistent specificity for Galleri in population-scale studies, are setting the stage for robust FDA approval and broad payer reimbursement, which could unlock significant new revenue streams and accelerate top-line growth.
Curious what growth path and margin shift could support that price tag for an unprofitable company with rising revenue and a rich implied future earnings multiple? The full narrative lays out how those moving parts feed into the $66 fair value and what would need to go right for GRAIL to grow into its current valuation premium.
Result: Fair Value of $66 (OVERVALUED)
Have a read of the narrative in full and understand what's behind the forecasts.
However, GRAIL still faces meaningful risks, including unresolved NHS Galleri trial questions and securities litigation that could weigh on confidence in the current equity story.
Find out about the key risks to this GRAIL narrative.
Next Steps
With sentiment on GRAIL clearly split between risks and rewards, it makes sense to move quickly and weigh the numbers yourself alongside the 2 key rewards and 3 important warning signs
Looking for more investment ideas beyond GRAIL?
If GRAIL has sharpened your focus on where capital works hardest, do not stop here. The right screener could surface opportunities you might otherwise miss.
- Target potential mispricings by scanning companies that look cheaper than their fundamentals suggest using the 44 high quality undervalued stocks.
- Strengthen your defense by focusing on companies with lower risk profiles through the 79 resilient stocks with low risk scores.
- Get ahead of the crowd by checking the screener containing 20 high quality undiscovered gems before others catch on.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com